Ann: 2023 Annual Report to shareholders, page-160

I don't mind this for FDA meeting, hypothetically it would be nice to walk into this meeting with the 2 additional trails Angleman and Pitt Hopkins complete with similar results as in PMS, whilst management have been extremely confident with 2591 it would certainly reinforce the quality of the drug with the FDA when designing phase 3 trail requirements for PMS.

I have always found management reference to this FDA meeting as a pivotal point for Neu's future, so this would make complete sense. From FDA meeting they get clear snap shot of what it looks like to go alone or partner for example before making a decision on the future either way.